Increased Nek1 expression in Renal Cell Carcinoma cells is associated with decreased sensitivity to DNA-damaging treatment
Open Access
- 25 May 2014
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (12) , 4283-4294
Abstract
Renal cell carcinoma (RCC) is a heterogeneous disease with resistance to systemic chemotherapy. Elevated expression of multiple drug resistance (MDR) has been suggested to be one of the mechanisms for this resistance. Here, we provide an alternative mechanism to explain RCC’s resistance to chemotherapy-induced apoptosis. Never-in mitosis A-related protein kinase 1 (Nek1) plays an important role in DNA damage response and proper checkpoint activation. The association of Nek1 with the voltage-dependent anion channel (VDAC1) is a critical determinant of cell survival following DNA-damaging treatment. We report here that Nek1 is highly expressed in RCC tumor and cultured RCC cells compared to that of normal renal tubular epithelial cells (RTE). The association between Nek1 and VDAC1 is genotoxic dependent: prolonged Nek1/VDAC1 dissociation will lead to VDAC1 dephosphorylation and initiate apoptosis. Down-regulation of Nek1 expression in RCC cells enhanced their sensitivity to DNA-damaging treatment. Collectively, these results suggest that the increased Nek1 expression in RCC cells maintain persistent VDAC1 phosphorylation, closing its channel and preventing the onset of apoptosis under genotoxic insults. Based on these results, we believe that Nek1 can serve as a potential therapeutic target for drug development in the treatment of RCC.Keywords
This publication has 44 references indexed in Scilit:
- The functions and regulation of the PTEN tumour suppressorNature Reviews Molecular Cell Biology, 2012
- Mutation of NIMA-related kinase 1 (NEK1) leads to chromosome instabilityMolecular Cancer, 2011
- Phosphorylation by Nek1 regulates opening and closing of voltage dependent anion channel 1Biochemical and Biophysical Research Communications, 2010
- Using molecular biology to develop drugs for renal cell carcinomaExpert Opinion on Drug Discovery, 2008
- The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast CancerCancer Research, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Phosphorylation of the Mitotic Regulator Protein Hec1 by Nek2 Kinase Is Essential for Faithful Chromosome SegregationJournal of Biological Chemistry, 2002
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997
- Mitochondrial control of apoptosisImmunology Today, 1997
- The mitochondrial permeability transitionBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1995